Synaffix B.V.
http://www.synaffix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Synaffix B.V.
Korea 2024 Outlook: Continued Focus On Drug Delivery Technologies
In a tough R&D environment, delivery technology-based new drug development activities by Korean firms are poised to remain robust in 2024.
Korea 2023 Review: R&D Potential Shines Through Despite Challenges
Despite some disappointments, the South Korean pharma industry showed mostly resilient R&D activity in 2023 amid robust efforts to secure technologies and assets in new modalities such as ADCs and TPD to better compete with global players.
Novartis Bags Chong Kun Dang’s HDAC6 Inhibitor In $1.3bn Deal
The deal marks the biggest out-licensing agreement ever for Chong Kun Dang, with the Swiss giant poised to explore the novel small molecule in various cardiovascular indications.
Deal Watch: Lilly Will Take Over Beam’s Rights To Verve Cardiovascular Assets
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice